The clinical utility of CDX2 was confirmed to be fairly specific for the identification of adenocarcinoma of the gastrointestinal tract, particularly colorectal adenocarcinoma, in the primary and metastatic setting [16]. Here, CDX2 is linked to colorectal adenocarcinoma.